Literature DB >> 2783559

Production of interleukin 1 activity by cultured human melanoma cells.

J L Bennicelli1, J Elias, J Kern, D Guerry.   

Abstract

A panel of melanoma cell lines derived from 7 primary and 20 metastatic lesions was tested for the production of interleukin 1 (IL-1) in standard mouse thymocyte costimulation assays. Constitutively produced IL-1 activity was found in the conditioned media of 4 of 7 primary and 5 of 20 metastatic melanoma cell lines tested. Four of 9 cell lines secreting IL-1 were also shown to contain cell-associated activity in their lysates. Melanoma-conditioned media were, however, unable to support the growth of CTLL, an interleukin 2-dependent cell line. The secreted IL-1 activity was significantly inhibited by antibodies to recombinant IL-1 alpha (3 of 3 lines), but not antibody to recombinant IL-1 beta. When conditioned medium from one cell line was fractionated on a Superose 12 column by fast protein liquid chromatography, a major peak of activity eluted at Mr 22,500-27,500. The presence of 2.2-kilobase mRNA hybridizing a probe for IL-1 alpha and 1.6-kilobase mRNA hybridizing a probe for IL-1 beta was detected by Northern blot in 3 of 4 secreting cell lines but not in a nonsecreting line. Taken together, these results suggest that cultured melanoma cells produce the cytokine IL-1 alpha, although the relationship between melanoma IL-1 and monocyte IL-1 is unclear. The production of IL-1 by melanoma cells is of interest because of its potential roles in the biology of melanoma through direct effects on tumor growth or through indirect effects on adjacent stromal and endothelial cells and infiltrating lymphoid cells.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2783559

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

1.  Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis.

Authors:  M Luca; S Huang; J E Gershenwald; R K Singh; R Reich; M Bar-Eli
Journal:  Am J Pathol       Date:  1997-10       Impact factor: 4.307

2.  Inhibition of colon carcinoma cell lung colony formation by a soluble form of E-selectin.

Authors:  G Mannori; D Santoro; L Carter; C Corless; R M Nelson; M P Bevilacqua
Journal:  Am J Pathol       Date:  1997-07       Impact factor: 4.307

3.  Expression of different immunological markers by cultured human melanocytes.

Authors:  N Smit; I Le Poole; R van den Wijngaard; A Tigges; W Westerhof; P Das
Journal:  Arch Dermatol Res       Date:  1993       Impact factor: 3.017

Review 4.  Adhesion molecules and their role in cancer metastasis.

Authors:  R M Lafrenie; M R Buchanan; F W Orr
Journal:  Cell Biophys       Date:  1993 Aug-Dec

5.  Interleukin 6: a fibroblast-derived growth inhibitor of human melanoma cells from early but not advanced stages of tumor progression.

Authors:  C Lu; M F Vickers; R S Kerbel
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-01       Impact factor: 11.205

Review 6.  Tissue factor as a tumor procoagulant.

Authors:  L V Rao
Journal:  Cancer Metastasis Rev       Date:  1992-11       Impact factor: 9.264

Review 7.  Growth factors in melanoma.

Authors:  U Rodeck; M Herlyn
Journal:  Cancer Metastasis Rev       Date:  1991-06       Impact factor: 9.264

Review 8.  Growth factor independence and growth regulatory pathways in human melanoma development.

Authors:  U Rodeck
Journal:  Cancer Metastasis Rev       Date:  1993-09       Impact factor: 9.264

9.  The addition of interleukin-2 to cyclophosphamide therapy can facilitate tumor growth of B16 melanoma.

Authors:  T Palomares; P Bilbao; A Alonso-Varona; E Barberá-Guillem
Journal:  Cancer Immunol Immunother       Date:  1995-05       Impact factor: 6.968

10.  Inflammatory signaling compromises cell responses to interferon alpha.

Authors:  W-C Huangfu; J Qian; C Liu; J Liu; A E Lokshin; D P Baker; H Rui; S Y Fuchs
Journal:  Oncogene       Date:  2011-06-13       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.